Yan Ren

Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

H. Handa, Y. Hirano, T. Hakoshima, 2014, Nature Structural &Molecular Biology.

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

M. Dhodapkar, D. Hansel, R. Das, 2015, Blood.

Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)

J. Reynolds, S. Couto, A. Spencer, 2019, Leukemia & lymphoma.

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

P. Sonneveld, R. Leguit, R. Raymakers, 2018, Haematologica.

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

A. Polonskaia, W. Pierceall, C. Bjorklund, 2019, Leukemia.

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Chin-Chun Lu, L. Hamann, M. Rolfe, 2018, Nature Chemical Biology.